Positive Correlation Between Serum IL-5 and TNF-alpha Levels and Churg-Strauss Syndrome Activity in Patients Successfully Treated with Montelukast

Lishchuk-Yakymovych, Khrystyna; Chopyak, Valentyna; Pukalyak, Roman; DuBuske, L.M.

doi:10.1016/j.jaci.2011.12.617

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theron also showed the effect of montelukast on the reduction of the serum level of TNF-α in patients with asthma (15). Lishchuk et al in 2012 showed that in patients with Churg-Strauss syndrome, after three months of treatment with montelukast, the serum TNF-α level decreased significantly, and the patient's pulmonary symptoms improved (16). However, in our study, despite a significant decrease in this cytokine in the montelukast group (within-group P < 0.001), a comparison of a reduction in both groups after intervention showed that this decrease was not significant (between-group P = 0.95).…”

Section: Discussionmentioning

confidence: 99%

A Double-blind Randomized Controlled Trial on the Effects of Montelukast on the Serum Level of Inflammatory Factors in Patients with Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is a major noncommunicable respiratory disease with diverse pulmonary and external pulmonary clinical manifestations. This disease is one of the leading causes of mortality in the world, and about 1% of the adult population suffers from COPD. Objectives: The aim of this study was to assess the effect of Montelukast on the serum level of inflammatory factors in patients with chronic obstructive pulmonary disease (COPD). Methods: In a randomized placebo-controlled trial, 74 patients with COPD with stable conditions were followed for two months after a random assignment to the placebo and montelukast (10 mg/d) groups. All patients continued their treatment protocol irrespective of their group to evaluate the effects of the addition of montelukast on serum levels of common inflammatory factors, such as Tumor Necrosis Factor alpha (TNF-α), C-reactive protein (CRP), and Interleukin 18 (IL-18) in COPD patients. SPSS 18 software was used for data analysis. Results of quantitative data were reported as mean ± standard deviation or median (interquartile range) and qualitative data as frequency (percentage). If the data distribution was normal, the paired t-test was used to compare the mean before and after and using an independent t-test to compare the mean changes between the two groups. The Mann-Whitney U test and Wilcoxon signed-rank test were also used if the data were not assumed to be normal. A P < 0.05 was considered as the level of significance. Results: At baseline, there were no significant differences in laboratory studies between the two groups. After two months of intervention, there was no evidence of decreased TNF-α and CRP in the montelukast group. IL-18 levels were not significantly different at the end of the study between the two groups (P = 0.23), but it had a decreasing trend in the montelukast group (from 20.25 ± 5.98 ng/ml to 16.19 ± 4.17 ng/ml, P < 0.001). Conclusions: Montelukast complementary therapy in COPD patients only improve the serum IL-18 levels and has not a reducing effect on the level of TNF-α and CRP evidenced by keeping their trend from baseline to the end of the study.

show abstract

Section: Discussionmentioning

confidence: 99%